ScheBo Biotech AG:
For More info on Schebo Products - Download Brochures
Schebo Biotech AG.is a rapidly growing high-tech biotechnology company founded in 1988. The company is dedicated to the development, production and worldwide distribution of innovative tests for both human and veterinary diagnostics, as well as food safety.
The antibody-based products of ScheBo® • Biotech are used in laboratories and hospitals all over the world. ScheBo® Biotech is developing, producing and distributing innovative tests (ELISA's) mainly for the diagnosis of gastro-enterological disorders.
In medical diagnostics, ScheBo Biotech is well-known for the Pancreatic Elastase 1 Stool Test (‘faecal elastase’), which is rapidly becoming recognized as the “gold standard” of non-invasive pancreatic function tests. Recent guidelines produced by the British Society of Gastroenterology, and the Association of Clinical Biochemist members, recommend this convenient, non-invasive, direct test of pancreatic exocrine function as "the test of first choice in patients who present with diarrhoea of putative pancreatic origin". Highly specific monoclonal antibodies to human Pancreatic elastase-1 enable quantitative determination using a single pea-sized stool sample, obviating lengthy urine or 72-hour stool collections. The development of the innovative Quick-Prep tubes has made sample preparation for the test considerably faster and more pleasant.
ScheBo® has developed a very exciting new assay for the screening of Colon cancer, namely the Fecal M2-PKElisa, and the serum M2-PK for follow-up monitoring after treatment. This test demonstrates a sensitivity and specificity of ~81%. The Fecal occult blood test ( FOBT) only gives information on bleeding tumours, whereas theM2-PK is indicative of any tumour activity in the colon, and the accumulated enzyme is measured in the stool. New and encouraging results from clinical studies with the non-invasive ScheBo Tumor M2-PK Stool Test, which is independent of occult blood, show high sensitivity combined with high specificity in colorectal cancer screening
The M2-PK Test measures the dimeric isoform of pyruvate kinase. The ScheBo Tumor M2-PK EDTA Plasma Test assists in monitoring the efficacy of therapy, patient follow-up and diagnosis in a wide range of different cancers, including gastrointestinal, breast, lung and urological tumours.
ScheBo® • Biotech AG developed and launched a highly specific and very sensitive test system for the detection of BSE-Risk Material (brain and spinal cord) in meat and meat products (BrainosticTM).
ScheBo® • Biotech has academic alliances with several universities and university hospitals in Europe, Israel, Canada and the United States of America
'Better' bowel cancer test found
Scientists believe they may have found a much more accurate way of diagnosing bowel cancer.
Researchers in Germany have discovered that a chemical from cancer tumours leaks into the bowel.
Writing in the British Journal of Cancer, they said this chemical, called Tumour M2-PK, can be found in the faeces of people with the disease. They said testing for the chemical could also enable doctors to find out how advanced the disease is. The UK Gvernment is currently considering introducing a bowel-screening programme.
One of the tests under consideration is the faecal occult blood test (FOBT). It is used to detect blood in the faeces - a symptom of bowel cancer. However, the test cannot tell whether the blood is caused by a tumour or whether it is the result of something less serious, such as piles. Only about six out of every 100 people with a single positive FOBT will have bowel cancer. This means that many people who do not have cancer may have to undergo unnecessary procedures.
Scientists at Giessen University Hospital, in Germany, believe their test is much more accurate. They obtained faecal samples from 204 patients who were about ot undergo colonoscopies, which involves inserting a tiny camera into the rectum. The colonoscopy established that 60 of these had bowel cancer. The scientists found that patients with the diesease had much higher levels of Tumour M2-PK.
The scientists say further research is needed.
There is currently much interest in this area of research
Professor Robert Souhami,
Cancer Research UK
Seite 1 von 2 BBC NEWS | Health|
"Better" bowel cancer test found'
"We found a significant difference in the level of Tumour M2-PK between those with a confirmed diagnosis of bowel cancer and those who were disease free," said Dr Phillip Hardt, who led the study.
"There was also a very strong link between the amount of enzyme found and how far the cancer had spread." The scientists are now planning further studies but they are confident their findings could lead to a new test for bowel cancer.
"We will now look to test Tumour M2-PK in a large trial, but his enzyme has the potential to be an excellent safety net," said Dr Hardt. "It could detect more cases of the disease and possibly save unnecessary medical procedures due to fewer false positive results."
Professor Robert Souhami, director of policy and communication at Cancer Research UK, which owns the British Journal of Cancer, welcomed the study. "There is currently much interest in this area of research," he said. "We hope that enzymes such as this one will eventually offer not only useful screening tools, but also an effective method of monitoring bowel cancer patients in remission, so that any return of disease can be quickly detected and acted upon."